DMAC
DiaMedica Therapeutics Inc.
$5.61
-0.53%
$302.3M
No data for this timeframe.
Vol
Market Cap$302.3M
Cap SizeSmall Cap
Inst. Holders6 funds
Inst. Value$11.4M
Inst. Activity3 buys / 0 sells
SEC Reports2
Recent Activity
Jun 1, 2026
Insider
Kuntz Richard sold 40,412 shares
Director @ $0.00 ($0.00)
Jun 1, 2026
Insider
Giuffre Randall Michael sold 40,412 shares
Director @ $0.00 ($0.00)
Jun 1, 2026
Insider
O'Connor Daniel J. sold 40,412 shares
Director @ $0.00 ($0.00)
May 6, 2026
SEC
DiaMedica reported Q1 2026 EPS of -$0.19, missing consensus of -$0.17 by 11.8%. Net loss widened to $10.0M from $7.7M a
8-K — Impact 6/10
Apr 1, 2026
SEC
Analysis based on filing metadata only — document content was unavailable
DEFA14A — Impact 3/10
Inst.
WELLS FARGO & COMPANY/MN — ADD
40,629 shares ($323.4K)
Inst.
BANK OF AMERICA CORP — DOUBLED
26,322 shares ($209.5K)
May 6, 2026
earnings_calendar
DMAC Q1 2026 Earnings After Market Close — 2026-05-06
Price Targets
Historical data — last covering-analyst action Nov 2025. No current recommendation available.
$15.50 (Nov 2025)
Current $5.42
Low $11.00
Median $13.00
High $25.00
4 analysts
$11.00
$25.00
Analyst Ratings
2Strong Buy
8Buy
1Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Nov 14, 2025 | Cantor Fitzgerald | INITIATE | Overweight |
| Aug 15, 2025 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Jul 18, 2025 | Craig-Hallum | MAINTAIN | Buy → Buy |
| Jul 18, 2025 | Lake Street | MAINTAIN | Buy → Buy |
| Jul 18, 2025 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.20 ▼ -5.3% | $-0.21 — $-0.19 | -11% YoY | 4 |
| Next Q | $-0.21 ▼ -3.7% | $-0.24 — $-0.19 | -25% YoY | 4 |
| Current FY | $-0.83 ▼ -3.4% | $-0.90 — $-0.76 | -19% YoY | 4 |
| Next FY | $-0.88 ▼ -5.3% | $-1.05 — $-0.58 | -6% YoY | 5 |
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $5.8M | TRIM |
| MORGAN STANLEY | $4.4M | DOUBLED |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $771.2K | DOUBLED |
| WELLS FARGO & COMPANY/MN | $323.4K | ADD |
| BANK OF AMERICA CORP | $209.5K | DOUBLED |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 1, 2026 | Kuntz Richard | A | $0.00 |
| Jun 1, 2026 | Giuffre Randall | A | $0.00 |
| Jun 1, 2026 | O'Connor Daniel | A | $0.00 |
| Jun 1, 2026 | Semba Charles | A | $0.00 |
| Jun 1, 2026 | Kellen Scott | A | $0.00 |
6 institutional holders with $11.4M total value (1,436,365 shares) as of 2025-Q4. Top holders: VANGUARD, MORGAN, CHARLES. Net buying activity: 3 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 723,120 | $5.8M | 50.3% | TRIM -56.7% |
| 2 | MORGAN STANLEY | 547,610 | $4.4M | 38.1% | DOUBLED +141.0% |
| 3 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 96,880 | $771.2K | 6.7% | DOUBLED +500.3% |
| 4 | WELLS FARGO & COMPANY/MN | 40,629 | $323.4K | 2.8% | ADD +85.1% |
| 5 | BANK OF AMERICA CORP /DE/ | 26,322 | $209.5K | 1.8% | DOUBLED +114.9% |
| 6 | FMR LLC | 1,804 | $14.4K | 0.1% | DOUBLED +1759.8% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| WELLS FARGO & COMPANY/MN | ADD | 21,947 | 40,629 | +85.1% | $323.4K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 12,249 | 26,322 | +114.9% | $209.5K | 2025-Q4 |
| FMR LLC | DOUBLED | 97 | 1,804 | +1759.8% | $14.4K | 2025-Q4 |
| VANGUARD GROUP INC | TRIM | 1,535,054 | 664,575 | -56.7% | $4.6M | 2025-Q3 |
| MORGAN STANLEY | DOUBLED | 240,476 | 579,585 | +141.0% | $4.0M | 2025-Q3 |
| WELLS FARGO & COMPANY/MN | ADD | 14,652 | 21,947 | +49.8% | $150.8K | 2025-Q3 |
| UBS Group AG | ADD | 8,266 | 13,340 | +61.4% | $91.6K | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | ADD | 8,497 | 12,249 | +44.2% | $84.2K | 2025-Q3 |
| MORGAN STANLEY | DOUBLED | 103,583 | 240,476 | +132.2% | $937.9K | 2025-Q2 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | DOUBLED | 13,253 | 79,553 | +500.3% | $310.3K | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | DOUBLED | 1,000 | 14,652 | +1365.2% | $57.1K | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 223 | 8,497 | +3710.3% | $33.1K | 2025-Q2 |
| UBS Group AG | ADD | 4,382 | 8,266 | +88.6% | $32.2K | 2025-Q2 |
| CITADEL ADVISORS LLC | DOUBLED | 25,213 | 55,500 | +120.1% | $210.3K | 2025-Q1 |
| UBS Group AG | DOUBLED | 1,769 | 4,382 | +147.7% | $16.6K | 2025-Q1 |
| UBS Group AG | NEAR_EXIT | 12,739 | 1,769 | -86.1% | $9.6K | 2024-Q4 |
| MORGAN STANLEY | ADD | 86,200 | 110,016 | +27.6% | $461.0K | 2024-Q3 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 13,251 | — | $55.5K | 2024-Q3 |
9 unique insiders with 0 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 1, 2026 | Kuntz Richard | Director | A | 40,412 | $0.00 | $0.00 |
| Jun 1, 2026 | Giuffre Randall Michael | Director | A | 40,412 | $0.00 | $0.00 |
| Jun 1, 2026 | O'Connor Daniel J. | Director | A | 40,412 | $0.00 | $0.00 |
| Jun 1, 2026 | Semba Charles Pauling | Director | A | 40,412 | $0.00 | $0.00 |
| Jun 1, 2026 | Kellen Scott | CFO & Secretary | A | 162,000 | $0.00 | $0.00 |
| Jun 1, 2026 | Krop Julie | Chief Medical Officer | A | 67,500 | $0.00 | $0.00 |
| Jun 1, 2026 | Pauls Dietrich John | President & CEO | A | 380,000 | $0.00 | $0.00 |
| Jun 1, 2026 | Lewis Tanya | Director | A | 40,412 | $0.00 | $0.00 |
| Jun 1, 2026 | Parsons James T. | Director | A | 51,189 | $0.00 | $0.00 |
2 SEC filing reports analyzed. Sentiment: 0 bullish, 1 bearish, 0 mixed, 1 neutral. Avg impact: 4.5/10.
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution (last covering-analyst action Nov 2025): 91% buy across 11 analysts — 2 strong buy, 8 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Nov 2025. No current recommendation available.
$15.50 mean target (Nov 2025)
$11.00 Low
$25.00 High
| Metric | Value |
|---|---|
| Current Price | $5.42 |
| Target Low | $11.00 |
| Target Mean | $15.50 |
| Target Median | $13.00 |
| Target High | $25.00 |
| # Analysts | 4 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.20 | $-0.21 | $-0.19 | -11.1% | -5.3% | 2↑ 0↓ | $0.0B | 0.0% | 4 |
| Next Q 2026-09-30 |
$-0.21 | $-0.24 | $-0.19 | -25.0% | -3.7% | 2↑ 1↓ | $0.0B | 0.0% | 4 |
| Current FY 2026-12-31 |
$-0.83 | $-0.90 | $-0.76 | -18.6% | -3.4% | 2↑ 2↓ | $0.0B | 0.0% | 4 |
| Next FY 2027-12-31 |
$-0.88 | $-1.05 | $-0.58 | -6.0% | -5.3% | 1↑ 2↓ | $0.0B | 0.0% | 5 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.200 | |
| 7d ago | $-0.190 | -0.010 |
| 30d ago | $-0.190 | -0.010 |
| 60d ago | $-0.207 | +0.007 |
| 90d ago | $-0.207 | +0.007 |
7 analyst firms have rated this stock: 1 upgrades, 1 downgrades, 5 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Nov 14, 2025 | Cantor Fitzgerald | INITIATE | — | Overweight |
| Aug 15, 2025 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Jul 18, 2025 | Craig-Hallum | MAINTAIN | Buy | Buy |
| Jul 18, 2025 | Lake Street | MAINTAIN | Buy | Buy |
| Jul 18, 2025 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| May 29, 2025 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Mar 19, 2025 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Nov 15, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Oct 10, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Oct 7, 2024 | HC Wainwright & Co. | INITIATE | — | Buy |
| Aug 16, 2024 | Oppenheimer | REITERATE | Outperform | Outperform |
| Mar 21, 2024 | Craig-Hallum | MAINTAIN | Buy | Buy |
| Mar 21, 2024 | Oppenheimer | REITERATE | Outperform | Outperform |
| Jun 22, 2023 | Oppenheimer | UPGRADE | Perform | Outperform |
| Jul 7, 2022 | Lake Street | MAINTAIN | — | Buy |
| Jul 7, 2022 | Craig-Hallum | MAINTAIN | — | Buy |
| Jul 7, 2022 | Oppenheimer | DOWNGRADE | Outperform | Perform |
| Jun 30, 2021 | Roth Capital | MAINTAIN | — | Buy |
| Apr 8, 2021 | Oppenheimer | INITIATE | — | Outperform |
| Feb 17, 2021 | Roth Capital | INITIATE | — | Buy |
| Jul 8, 2020 | Maxim Group | INITIATE | — | Buy |
| May 15, 2020 | Craig-Hallum | MAINTAIN | — | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 8 | 1 | 0 | 0 | 91% | |
| May 1, 2026 | 2 | 8 | 1 | 0 | 0 | 91% | |
| Apr 1, 2026 | 2 | 8 | 1 | 0 | 0 | 91% | |
| Mar 1, 2026 | 2 | 8 | 1 | 0 | 0 | 91% | |
| Feb 1, 2026 | 2 | 8 | 1 | 0 | 0 | 91% | |
| Jan 1, 2026 | 2 | 8 | 1 | 0 | 0 | 91% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 6, 2026
earnings_calendar
DMAC Q1 2026 Earnings After Market Close — 2026-05-06
Mar 31, 2026
earnings_calendar
DMAC Q4 2025 Earnings After Market Close — 2026-03-31
Mar 30, 2026
earnings_calendar
DMAC Q4 2025 Earnings After Market Close — 2026-03-30